What is the serologic prevalence of SARS CoV-2 in states with high and low disease burdens in Nigeria?
In this cross-sectional study including 4904 participants, a high seroprevalence of 78.9% was obtained across 12 states in Nigeria. Seropositivity was consistent across the states surveyed, ranging from 69.8% in Lagos to 87.7% in Borno.
The results from this study suggest that COVID-19 infection is prevalent in Nigeria despite the low hospitalization rate recorded at the time of sampling.
The global impact of COVID-19 has led to an increased need to continuously assess disease surveillance tools. The utility of SARS-CoV-2 serologic tools in determining immunity levels across different age groups and locations in helping to quickly assess the burden of COVID-19 with significant health policy implications is unknown.
To determine the prevalence of SARS-CoV-2 antibodies with respect to the age group and sex of participants.
Design, Setting, and Participants
A cross-sectional survey of 4904 individuals across 12 states with high and low COVID-19 disease burden in Nigeria was carried out between June 29 and August 21, 2021.
Main Outcomes and Measures
Enzyme-linked immunosorbent assay was used for the detection of specific SARS-CoV-2 immunoglobulin G and immunoglobulin M antibodies, such as the nucleocapsid protein-NCP and spike protein S1. Interviewer-administered questionnaires provided information on participants’ history of disease and associated risk factors.
A total of 4904 individuals participated in the study (3033 were female [61.8%]; mean [SD] age, 26.7 [6.51] years). A high seroprevalence of SARS-CoV-2 (78.9%) was obtained. Seropositivity was consistent across the states surveyed, ranging from 69.8% in Lagos to 87.7% in Borno. There was no association between sex and seropositivity (female, 2414 [79.6%]; male, 1456 [77.8%]; P = .61); however, an association was noted between age and seropositivity, with the peak prevalence observed in participants aged 15 to 19 years (616 [83.6%]; P = .001). Similarly, loss of appetite (751 [82.3%]; P = .04) and smell (309 [84.4%]; P = .01) were associated with seropositivity.
Conclusions and Relevance
In this cross-sectional study, a high SARS-CoV-2 seroprevalence was obtained among the study population during the low level of vaccination at the time of the survey. Thus, there is a need for both an efficacy and antibody neutralization test study to ascertain the efficacy of the antibody detected and the potential for herd immunity in Nigeria.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: August 26, 2022.
Published: October 11, 2022. doi:10.1001/jamanetworkopen.2022.36053
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Kolawole OM et al. JAMA Network Open.
Corresponding Authors: Olatunji Matthew Kolawole, PhD, Microbiology, University of Ilorin, Ilorin, Main Campus, Ilorin, Kwara state 240003, Nigeria (email@example.com); Oyewale Tomori, PhD, Redeemer’s University, EDE, ACEGID, University Road, Gbongan-Osogbo Road, Akoda, Ede, OSUN 232103, Nigeria (firstname.lastname@example.org).
Author Contributions: Dr Kolawole had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Kolawole, Tomori, Agbonlahor, Ekanem, Abdulsalam, Okojie, Braide, Uzochukwu, Bello, Shehu, Gureje, Onwujekwe, Onyedum, Ezike, Bukbuk, Amazigo, Habib, Ufere, Azodoh.
Acquisition, analysis, or interpretation of data: Kolawole, Tomori, Agbonlahor, Ekanem, Bakare, Abdulsalam, Braide, Uzochukwu, Rafindadi, Bello, Shehu, Gureje, Lecky, Onwujekwe, Onyedum, Ezike, Bukbuk, Ashir, Anyaehie, Amazigo, Habib, Azodoh.
Drafting of the manuscript: Kolawole, Ekanem, Abdulsalam, Uzochukwu, Lecky, Ashir, Anyaehie, Habib, Ufere, Azodoh.
Critical revision of the manuscript for important intellectual content: Kolawole, Tomori, Agbonlahor, Ekanem, Bakare, Abdulsalam, Okojie, Braide, Uzochukwu, Rafindadi, Bello, Shehu, Gureje, Onwujekwe, Onyedum, Ezike, Bukbuk, Ashir, Anyaehie, Amazigo, Habib, Ufere.
Statistical analysis: Kolawole, Tomori, Okojie, Braide, Uzochukwu, Bello, Shehu, Onwujekwe, Ezike, Bukbuk, Ashir, Habib.
Obtained funding: Kolawole, Tomori, Ufere, Azodoh.
Administrative, technical, or material support: Kolawole, Tomori, Agbonlahor, Ekanem, Bakare, Braide, Bello, Shehu, Lecky, Onwujekwe, Onyedum, Ezike, Bukbuk, Ashir, Anyaehie, Amazigo, Ufere, Azodoh.
Supervision: Kolawole, Tomori, Agbonlahor, Ekanem, Abdulsalam, Okojie, Braide, Uzochukwu, Rafindadi, Shehu, Gureje, Lecky, Onwujekwe, Onyedum, Ezike, Bukbuk, Ashir, Anyaehie, Habib, Azodoh.
Conflict of Interest Disclosures: No disclosures were reported.
Funding/Support: This study was funded by a grant from the World Health Organization (WHO)-AFRO (AFNGA2018479-Award 70397).
Role of the Funder/Sponsor: The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We acknowledge Jeremiah Ikhevha Ogah, PhD, for creating the online platform for data entry, collation, and analysis of the data for this project; financial compensation was provided. We appreciate the contributions of WHO state coordinators in Nigeria and the Ministries of Health and Education in Abuja, Kwara, Kaduna, Sokoto, Edo, Akwa-Ibom, Lagos, Ondo, Enugu, Imo, Borno, and Yobe states. Acknowledgments also go to Lahor Research Diagnostics & Environmental Ltd and Biosensors Medical Diagnostics Ltd for their role in the laboratory analysis of the samples.
You currently have no searches saved.
You currently have no courses saved.